委外研發機構市場規模、佔有率、成長分析（按類型、治療領域、最終用戶和地區）- 2025 年至 2032 年行業預測

2023 年全球委外研發機構市場規模價值 613 億美元，預計將從 2024 年的 663.9 億美元成長到 2032 年的 1256.4 億美元，預測期內（2025-2032 年）的複合年成長率為 8.3%。

由於醫療保健外包趨勢日益增強以及全球製造成本不斷上升，委外研發機構(CRO) 市場預計將經歷顯著成長。預計對醫學研究和臨床試驗的投資增加將增加 CRO 的商業機會。藥物開發的複雜性將進一步增加對CRO的需求，使醫療保健提供者能夠降低成本，同時提高盈利。此外，新興市場良好的法規環境為業務擴展提供了新的途徑。然而，他們面臨著智慧財產權問題、對製藥公司的依賴以及 CRO 之間的激烈競爭等挑戰。整體而言，機會很多，但相關人員必須克服這些限制因素，才能充分利用市場的巨大潛力。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術分析

藥物委外研發機構市場規模（按類型和複合年成長率）（2025-2032）

• 市場概覽
• 藥物研發
  • 目標檢驗
  • 線索識別
  • 先導藥物最適化
  • 其他
• 臨床前
• 臨床
  • 第一階段試驗服務
  • 第二階段檢測服務
  • III期臨床試驗服務
  • 第四階段檢測服務
• 其他

委外研發機構市場規模（依治療領域及複合年成長率）（2025-2032）

• 市場概覽
• 腫瘤學
• 心臟病學
• 感染疾病
• 神經病學
• 免疫疾病
• 胃腸病學和肝病學
• 其他

藥物委外研發機構市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 製藥和生物技術公司
• 醫療設備公司
• 其他

藥物委外研發機構市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• IQVIA（USA）
• ICON plc（Ireland）
• Charles River Laboratories（USA）
• Medpace（USA）
• Fortrea（USA）
• Parexel（USA）
• Syneos Health（USA）
• Thermo Fisher Scientific（USA）
• PPD Inc.（USA）
• Labcorp Drug Development（USA）
• Eurofins Scientific（France）
• SGS SA（Switzerland）
• PSI CRO AG（Switzerland）
• Novotech（Australia）
• KCR SA（Poland）
• Linical Co., Ltd.（Japan）
• Pharmaron（China）
• WuXi AppTec（China）
• WuXi Biologics（China）
• Tigermed（China）

結論和建議

Global Contract Research Organization Market size was valued at USD 61.3 billion in 2023 and is poised to grow from USD 66.39 billion in 2024 to USD 125.64 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The contract research organization (CRO) market is poised for significant growth driven by the increasing trend of outsourcing in healthcare and surging global manufacturing costs. Investments in medical research and a rise in clinical trials are anticipated to enhance business opportunities for CROs. The intricate nature of drug development further fuels demand for these organizations, enabling healthcare providers to reduce costs while enhancing profitability. Additionally, favorable regulatory environments in emerging markets present new avenues for expansion. However, the market faces challenges from intellectual property concerns, reliance on pharmaceutical firms, and intense competition among CROs. Overall, while opportunities abound, stakeholders must navigate these restraints to capitalize on the market's promising potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Research Organization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contract Research Organization Market Segments Analysis

Global Contract Research Organization Market is segmented by Type, Therapeutic Area, End-User and region. Based on Type, the market is segmented into Drug Discovery, Pre-Clinical, Clinical and Others. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Infectious Disease, Neurology, Immunological Disorders, Gastroenterology and Hepatology and Others. Based on End-User, the market is segmented into Pharmaceutical and Biotechnological Companies, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contract Research Organization Market

The global contract research organization (CRO) market is significantly driven by the rising trend of outsourcing within the healthcare sector, especially as the demands on healthcare systems continue to escalate. Pharmaceutical and biotechnology companies are increasingly turning to CROs for their clinical trials, drug development, and regulatory services. This strategic shift allows these companies to lower expenses, tap into specialized knowledge, and accelerate the process of bringing new products to market. As a result, the reliance on CROs is intensifying, fostering growth within the industry and enhancing collaborative opportunities between pharmaceutical firms and research organizations.

Restraints in the Global Contract Research Organization Market

As intellectual property rights tighten in the pharmaceutical and biotech sectors, companies may grow increasingly apprehensive about the security of their proprietary information when outsourcing to contract research organizations (CROs). This heightened concern over the protection of intellectual property could pose a significant challenge to the growth of the global CRO market. If companies perceive the risk of intellectual property theft or misuse to be too high, they may hesitate to engage with CROs, which can ultimately hinder market expansion and limit collaboration in research and development efforts within these industries in the foreseeable future.

Market Trends of the Global Contract Research Organization Market

The Global Contract Research Organization (CRO) market is witnessing a significant trend toward the integration of Artificial Intelligence (AI) and machine learning technologies. These advancements are revolutionizing clinical trial processes by enhancing trial design, optimizing patient recruitment, and streamlining data analysis, resulting in improved efficiency and accuracy. The increased adoption of AI enables CROs to automate various business functions, reducing operational costs and expediting project timelines. This technological shift is not only transforming how CROs operate but also enhancing the drug development pipeline, ultimately driving growth in the market as stakeholders seek innovative solutions for complex clinical challenges.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Contract Research Organization Market Size by Type & CAGR (2025-2032)

• Market Overview
• Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead Optimization
  • Others
• Pre-Clinical
• Clinical
  • Phase I Trial Services
  • Phase II Trial Services
  • Phase III Trial Services
  • Phase IV Trial Services
• Others

Global Contract Research Organization Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Cardiology
• Infectious Disease
• Neurology
• Immunological Disorders
• Gastroenterology and Hepatology
• Others

Global Contract Research Organization Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical and Biotechnological Companies
• Medical Device Companies
• Others

Global Contract Research Organization Market Size & CAGR (2025-2032)

• North America (Type, Therapeutic Area, End-User)
  • US
  • Canada
• Europe (Type, Therapeutic Area, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fortrea (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PSI CRO AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novotech (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KCR S.A. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Linical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tigermed (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations